Topotecan

 

Topotecan monotherapy is indicated for the treatment of
• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.
• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line 
regimen is not considered appropriate (see section 5.1).
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix 
recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to 
cisplatin require a sustained treatment free interval to justify treatment with the combination (see 
section 5.1).

Topotecan monotherapy is indicated for the treatment of

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

View the SPC...

Download the Topotecan SPC. You will need Adobe Reader to view this document.

Get "SPC Topotecan 01_2016.pdf"...

Download

Medicines Information Request

Click here to fill in a medicines information form about this product